Publications in collaboration with researchers from Instituto de Investigación Sanitaria Biobizkaia (22)

2024

  1. Efficacy and safety of long-acting injectable versus oral antipsychotics in the treatment of patients with early-phase schizophrenia-spectrum disorders: a systematic review and meta-analysis

    Therapeutic Advances in Psychopharmacology, Vol. 14

  2. Emotional intelligence and neurocognition profiles in first-episode psychosis: A two-year follow-up study

    European Neuropsychopharmacology, Vol. 85, pp. 66-77

  3. Gender sensitivity of the COVID-19 mental health research in Europe: a scoping review

    International Journal for Equity in Health, Vol. 23, Núm. 1

2023

  1. Clinical Management and Assessment of the Early Stages of Psychosis: A Multidimensional Approach

    Methods in molecular biology (Clifton, N.J.), Vol. 2687, pp. 141-150

  2. First-episode psychosis intervention programme versus standard care for the clinical management of early phases of psychosis: Cost analysis

    BJPsych Open, Vol. 10, Núm. 1

  3. Gender differences in the management of acute psychiatric episodes in the emergency department: a cross-sectional analysis of the 2017–2019 triennium

    Archives of Women's Mental Health, Vol. 26, Núm. 6, pp. 777-783

  4. Isolation and Differentiation of Neurons and Glial Cells from Olfactory Epithelium in Living Subjects

    Molecular Neurobiology, Vol. 60, Núm. 8, pp. 4472-4487

  5. Letter to the editor: Gwinnutt JM, Toyoda T, Barraclough M, Verstappen SMM, Hornberger M, MacGregor A. Cognitive impairment in the immune-mediated inflammatory diseases compared with age-matched controls: Systematic review and meta-regression

    Seminars in Arthritis and Rheumatism

  6. Neuropsychological and Functional Assessment of Cognitive Impairments in Schizophrenia

    Methods in molecular biology (Clifton, N.J.), Vol. 2687, pp. 127-139

  7. Psychosis and substance abuse increase the COVID-19 mortality risk

    Psychological Medicine, Vol. 53, Núm. 9, pp. 4236-4244

  8. Violence in first-episode psychosis: Evidence from an early intervention in psychosis programme

    BJPsych Open, Vol. 9, Núm. 5

2021

  1. Characterization of dopamine D2 receptor coupling to G proteins in postmortem brain of subjects with schizophrenia

    Pharmacological Reports, Vol. 73, Núm. 4, pp. 1136-1146

  2. Cognitive Enhancers in Schizophrenia: A Systematic Review and Meta-Analysis of Alpha-7 Nicotinic Acetylcholine Receptor Agonists for Cognitive Deficits and Negative Symptoms

    Frontiers in Psychiatry, Vol. 12

  3. Gender-Based Analysis of the Psychological Impact of the COVID-19 Pandemic on Healthcare Workers in Spain

    Frontiers in Psychiatry, Vol. 12

  4. Long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report

    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, Vol. 11

  5. Oral and Palmitate Paliperidone Long-Acting Injectable Formulations' Use in Schizophrenia Spectrum Disorders: A Retrospective Cohort Study from the First Episode Psychosis Intervention Program (CRUPEP)

    International Journal of Neuropsychopharmacology, Vol. 24, Núm. 9, pp. 694-702

2020

  1. Deafness and mental health: Clinical challenges during the COVID-19 pandemic.

    Psychological Trauma: Theory, Research, Practice, and Policy, Vol. 12, pp. S212-S213

2019

  1. Long-acting injectable second-generation antipsychotics in first-episode psychosis: A narrative review

    International Clinical Psychopharmacology, Vol. 34, Núm. 2, pp. 51-56

2018

  1. Cognitive impairment in patients with neuropsychiatric and non-neuropsychiatric systemic lupus erythematosus: A systematic review and meta-analysis

    Journal of the International Neuropsychological Society, Vol. 24, Núm. 6, pp. 629-639

  2. Therapeutic Drug Monitoring of Second-Generation Antipsychotics for the Estimation of Early Drug Effect in First-Episode Psychosis: A Cross-sectional Assessment

    Therapeutic Drug Monitoring, Vol. 40, Núm. 2, pp. 257-267